Cita APA

Sarntivijai, S., Zhang, S., Jagannathan, D. G., Zaman, S., Burkhart, K. K., Omenn, G. S., . . . Abernethy, D. R. (2016). Linking MedDRA®-coded Clinical Phenotypes to Biological Mechanisms by The Ontology of Adverse Events: A pilot study on Tyrosine Kinase Inhibitors (TKIs). Drug Saf.

Citación estilo Chicago

Sarntivijai, Sirarat, Shelley Zhang, Desikan G. Jagannathan, Shadia Zaman, Keith K. Burkhart, Gilbert S. Omenn, Yongqun He, Brian D. Athey, y Darrell R. Abernethy. "Linking MedDRA®-coded Clinical Phenotypes to Biological Mechanisms By The Ontology of Adverse Events: A Pilot Study On Tyrosine Kinase Inhibitors (TKIs)." Drug Saf 2016.

Cita MLA

Sarntivijai, Sirarat, et al. "Linking MedDRA®-coded Clinical Phenotypes to Biological Mechanisms By The Ontology of Adverse Events: A Pilot Study On Tyrosine Kinase Inhibitors (TKIs)." Drug Saf 2016.